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Resumo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A doença de Alzheimer é a forma mais comum de demência a 
nível mundial. Clinicamente, caracteriza-se por declínio 
cognitivo, alterações de personalidade e humor, e 
desorientação. Neuropatologicamente, esta doença 
neurodegenerativa caracteriza-se pela acumulação 
extracelular do péptido beta-amilóide (βA), com formação de 
placas senis, e pela acumulação intracelular da proteína Tau 
hiperfosforilada formando tranças neurofibrilares. A patologia 
afeta maioritariamente o hipocampo, podendo progredir para 
o córtex cerebral. Estudos recentes mostram que a 
desregulação da acetilação das histonas está associada ao 
aumento da compactação da cromatina, com a consequente 
diminuição da transcrição génica. Assim, o estudo dos 
inibidores de enzimas que promovem a deacetilação das 
histonas, as HDAC (do inglês histone deacetylase), tem vindo 
a ganhar interesse como potenciais terapias contra a doença de 
Alzheimer. Para além disto, o péptido βA induz a produção de 
espécies reativas de oxigénio (ERO), tais como o peróxido de 
hidrogénio (H2O2), que promovem a atividade do fator de 
transcrição Nrf2 (do inglês nuclear factor erythroid 2-related 
factor 2), alterando assim a resposta antioxidante. Nesta 
perspetiva, neste estudo pretendemos avaliar o efeito de um 
inibidor das HDAC, o butirato de sódio (SB, do inglês sodium 
butyrate) (1 mg/kg/dia, durante 42 dias), na modificação dos 
sintomas e neuropatologia associados à doença de Alzheimer, 
utilizando o murganho triplo transgénico para a doença de 
Alzheimer (3xTg-AD). 
 
Doença de Alzheimer, deacetilases de histonas, butirato de 
sódio, murganho 3xTg-AD 
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Os animais 3xTg-AD com 10.5 meses de idade apresentaram 
um nível elevado de ansiedade em comparação com animais 
não transgénicos (wild-type, WT), que não foi minimizado 
pelo tratamento com SB. Por outro lado, em testes 
comportamentais que permitem avaliar processos 
mnemónicos, como o labirinto em Y (Y-maze), o 
reconhecimento de novos objetos e o teste de deslocação de 
objetos, não se observaram alterações significativas nos 
animais 3xTg-AD. A determinação dos níveis de acetilação 
da histona H3, dos níveis da proteína Tau total e fosforilada, 
assim como os níveis de Nrf2 nestes animais, com recurso à 
técnica de Western blotting mostrou que não só não existiam 
diferenças entre os animais 3xTg-AD e animais controlo 
wild-type, como o tratamento dos animais 3xTg-AD com SB 
não afetou nenhum destes parâmetros. Para tentar explicar a 
inexistência de diferenças entre os animais 3xTg-AD e WT 
avaliou-se a presença de agregados de βA e de Tau 
hiperfosforilada por imunohistoquímica nos animais 3xTg-
AD. Porém, não se verificou a presença de marcadores 
histopatológicos da doença nestes animais. A explicação 
mais provável para estes resultados poderá ser um atraso no 
desenvolvimento da doença causado pelo aparecimento mais 
tardio dos marcadores histopatológicos e das alterações 
comportamentais, como sugerido na literatura recente sobre 
este modelo transgénico. 
Futuramente, será necessária a realização deste estudo num 
modelo animal que apresente uma progressão mais acelerada 
da patologia, nomeadamente no murganho transgénico 
APP/PS1. 
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Alzheimer’s disease is the commonest form of 
dementia worldwide. Clinically, this neurodegenerative 
disorder is characterized by cognitive decline, changes in 
personality and mood, and disorientation. 
Neuropathologically, it is characterized by the 
extracellular accumulation of beta-amyloid peptide (Aβ) 
forming senile plaques, and the intracellular deposition of 
hyperphosphorylated Tau protein forming neurofibrillary 
tangles. Alzheimer’s disease affects primarily the 
hippocampus and may progress towards the cerebral 
cortex. Recent studies showed that deregulation of histone 
acetylation is associated with increased chromatin 
compaction and the subsequent decrease in gene 
transcription. Thus, the study of inhibitors of enzymes that 
promote histone deacetylation, HDACs (Histone 
DeACetylases) became a matter of interest in Alzheimer’s 
disease therapeutics. Besides, it was shown that Aβ peptide 
induces the production of reactive oxygen species (ROS), 
such as hydrogen peroxide (H2O2), that further promote the 
activity of the Nrf2 (nuclear factor erythroid 2-related 
factor 2) transcription factor, altering cellular/tissue 
antioxidant profile. In this perspective, in this study we 
aimed to evaluate the possible effect of a HDAC inhibitor, 
sodium butyrate (SB) (1 mg/kg/day, for 42 days), in the 
attenuation of Alzheimer’s disease-related symptoms and 
neuropathology, using the triple transgenic mice for 
Alzheimer’s disease (3xTg-AD). 
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3xTg-AD mice at 10.5 months of age showed increased 
anxiety levels associated to the disease in comparison to 
non-transgenic/wild-type (WT) mice, that was not reverted 
by treatment with SB. Memory processes analysed through 
the Y-maze, the novel object recognition and object 
displacement tests showed no alterations in 3xTg-AD 
animals nor after treatment with SB. Quantification of 
acetylation levels of histone H3, the levels of total and 
phosphorylated Tau, as well as Nrf2 levels showed no 
significant differences between control and 3xTg-AD 
animals either. Treatment of 3xTg-AD mice with SB did 
not significantly affect any of these parameters either. 
Aiming to explain the lack of behavioural and biochemical 
differences between the 3xTg-AD and WT animals, the 
presence of Aβ aggregates and hyperphosphorylated Tau 
were assessed by immunohistochemistry in the 
hippocampus of 3xTg-AD mice. However, we did not 
observe any histopathological markers associated with this 
neurodegenerative disorder. The most probable 
explanation for these results is a delay in the disease 
development, leading to a later appearance of brain 
histopathological markers and behavioural alterations, as 
suggested by recent literature. 
In future studies, it will be interesting to analyse an animal 
model with a more severe pathological progression, such 
as the APP/PS1 transgenic mice. 
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1. Alzheimer’s disease  
 
1.1 Epidemiology  
Dementia is one of the major causes of disability in age-dependent human brain 
diseases. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most 
common form of dementia (Maloney and Lahiri, 2011). Currently, AD is the most frequent 
cause of dementia in Western societies (Mayeux and Stern, 2012). 
According to the World Alzheimer Report of 2018, 50 million people in the world 
live with dementia, a value that will duplicate by 2030 and triplicate by 2050. Thus, by 2050 
about 152 million people are anticipated to suffer from dementia. These drastic figures stem 
from the fact that the population is becoming increasingly aged, due to the improvement in 
the health systems at world level, strongly contributing to an increase in life expectancy. 
Although elderly people are most of the AD-affected population, it is noteworthy that 
dementia is not a natural or normal part of aging, but a neurodegenerative condition that 
accentuates with aging. Between 2011 and 2013, the average life expectancy at birth of the 
resident population in Portugal was 80 years, an increase of approximately 3 years, compared 
to the previous decade (Santana et al., 2015).  
 
 
 
Figure 1- The growth in the number of people with dementia in high-, low- and middle-income countries. 
Source: World Alzheimer Report, 2015. 
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1.2 Forms and stages of AD 
AD can be divided in two types: familial Alzheimer’s disease (FAD) and sporadic 
Alzheimer’s disease (SAD) (Masters et al., 2015). Familial forms of AD usually occur before 
the age of 65 and accounts for only 1% of AD cases (Chen et al., 2013b); AD-related 
mutations can affect one of three genes, amyloid precursor protein (APP), presenilin 1 (PS1) 
and presenilin 2 (PS2) (Reitz and Mayeux, 2014; Masters et al., 2015). SAD is the most 
common form of AD and usually manifests after the age of 65 (Khemka et al., 2015). The 
aetiology of this sporadic form is very limited, but several risk factors have been identified, 
such as aging and specific cardiovascular diseases (Bekris et al., 2010). Because the burden 
of SADs increases with age, many researchers have postulated that oxidative stress may be 
involved in the process of aging. 
 
AD patients are clinically subdivided into four stages as mild cognitive impairment 
(MCI), mild, moderate and severe AD (Park and Moon, 2016). In the first stage, a person 
may represent amnestic symptoms or problems of concentration, such as forgetting familiar 
words or the location of everyday objects (Selkoe and Schenk, 2003). The second stage 
(moderate stage) can last for many years, dementia symptoms are more pronounced, and the 
person may have difficulty performing everyday tasks. In the third stage (late stage), 
dementia symptoms are severe. People are completely dependent on caregivers because they 
lose the ability to respond to their environment and to communicate (Lancet, 2011).  
Histopathologically, both FAD and SAD forms are identical, both being 
characterized by brain atrophy and by the presence of amyloid plaques and neurofibrillary 
tangles (NFT) (Reddy, 2006; Masters et al., 2015). Under normal conditions there is a 
balance between the production and degradation of β-amyloid peptide (Aβ), in order to avoid 
its accumulation. With aging, Aβ levels in the brain as well as the degree of lesions 
associated with Tau protein begin to increase (Figure 2). In addition to these, brain atrophy 
and memory decline are also already visible factors in this state. Patients with MCI 
corresponds to a degree of cognitive impairment in memory, function or language (Albert et 
al., 2011). After several years of progressive memory decline, patients begin to experience 
deficits in motor function, disorientation, memory impairment and global cognitive deficits. 
As the severity of the disease increases, Aβ levels in the cerebrospinal fluid (CSF) decrease, 
as a result of the aggregation of the peptide in the brain, while Tau and phosphorylated Tau 
Vera Martinho 
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(pTau) levels increase in the CSF (Tarawneh and Holtzman, 2012; Khemka et al., 2015). 
Brain atrophy as well as memory deficit are also increased on a large scale, facilitating the 
diagnose of AD. 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Causes of AD and risk factors 
The major risk factor for the development of AD is age (Guerreiro and Bras, 2015); 
indeed, most cases of AD are observed in people aged 65 years or older (Chen et al., 2013a). 
Between 65 and 74 years of age, approximately 1% of people have AD, mostly 
corresponding to FAD; in people older than 85 years, the risk increases to 50%. In addition 
to aging, there are other factors associated with an increased risk for AD, such as 
cardiovascular disease, stroke, cerebral haemorrhage, hypertension, smoking, 
hyperglycemia and obesity (Table 1) (Khan et al., 2016). These factors decrease the quality 
of reasoning, memory, language, as well as emotional control. 
Hypertension and cholesterol increase the risk of developing AD potentially due to 
the damage in blood vessels in the brain, causing less blood flow and death of brain tissue 
(Torre, 2012). Another risk factor in SAD is hyperglycemia linked to type II diabetes, which 
may be linked to partial or complete insulin resistance, leading to brain neuronal damage 
(Chen et al., 2009; Querfurth and LaFerla, 2010). 
 
Figure 2- Towards defining a preclinical stage of AD. Taken from http://www.gepezz.info/similar/mild-
cognitive-impairment-sciencedirect.html. 
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Table 1- Factors that modify the risk of AD. Adapted from (Khan et al., 2016) 
Risk factor Possible mechanisms 
Cardiovascular 
disease 
↑ Aβ deposition 
Smoking 
Cerebrovascular effects 
Oxidative stress 
Hypertension Microvascular disease 
Type II diabetes 
Cerebrovascular effects 
Insulin and Aβ compete for clearance 
Obesity Increased risk of type II diabetes inflammatory 
Traumatic head 
injury 
↑ Aβ and APP deposition 
 
The clinical diagnosis of AD is usually performed through the assessment of signs and 
symptoms in the patient, such as memory loss and difficulty caring for oneself. For an 
accurate diagnosis it is necessary to examine brain tissue, however, a combination of 
different clinical evaluations such as mental, behavioral and physical tests, and radiological 
methods, may be applied (Mayeux, 2004; Taipa et al., 2012). 
The first step in a diagnosis is to assess the patient's history. It is necessary to determine 
what symptoms are present, when they started and how they progressed over time. Physical 
examinations are also performed, including blood, CSF and urine tests. These analyses are 
very important because they will allow the identification of Aβ and pTau levels, two 
biomarkers of AD in the CSF (Albert et al., 2011). Structural imaging tests are also useful, 
including magnetic resonance imaging (MRI) and computed tomography (CT), which 
provide information about the shape and volume of the brain. Functional magnetic resonance 
imaging (fMRI) or positron emission tomography (PIB-PET) may also be used to 
complement the morphological studies (Jack Jr et al., 2010; Albert et al., 2011). However, 
only patients with persistent or progressive loss complaint of memory, confusion and 
difficulty performing standard cognitive tests may undergo imaging tests. The level of 
precision for diagnosis of AD is high because the disease can develop due to genetic, 
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environmental or lifestyle factors; imaging tests and biomarkers can be performed thus 
allowing a possible AD diagnosis (Mayeux, 2004; Dubois et al., 2007).  
 
1.4 Pathology of AD 
The clinical hallmarks of the disease are memory loss, cognitive impairment and altered 
language, visuospatial skills, executive function and personality (Hardy, 2006; Maloney and 
Lahiri, 2011), most probably related with irreversible loss of neurons in the hippocampus, 
progressing to the cortex. 
The pathological hallmarks are the presence of neuritic plaques (Figure 3A), which 
are predominantly composed of Aβ peptide and NFTs (Figure 3B), composed of 
hyperphosphorylated microtubule-associated Tau (τ) protein (MAPT) (Oddo et al., 2003). 
 
 
 
 
 
 
 
 
1.4.1 Production of amyloid-beta peptide 
APP is a type 1 membrane glycoprotein that plays an important role in a range of 
biological activities such as signaling, intracellular transport and neuronal development. Aβ 
peptide results from the processing of APP (Chen et al., 2017). There are two proteolytic 
processing pathways of APP (Figure 4). In the nonamyloidogenic pathway, APP is initially 
cleaved by the α-secretase leading to the production of soluble form of APP (sAPPα) and a 
carboxyl-fragment (C83). Subsequently, the C83 fragment is cleaved by ɣ-secretase, 
producing the intracellular domain of APP (AICD) (Barage and Sonawane, 2015). In the 
amyloidogenic pathway, APP is cleaved by β-secretase and releases the large extracellular 
domain of APP, generating a C-terminal fragment composed by 99 residues (C99), that is 
Figure 3- Pathological hallmarks of AD. Numerous neuritic plaques (black arrows) (A) and neurofibrillary 
tangles (NFT) (red arrows) (B). Adapted from (Perl, 2010). 
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then cleaved by γ-secretase within the transmembrane domain to produce Aβ and AICD 
(Chen et al., 2013a, 2017). 
Figure 4- Proteolytic processing of APP in amyloidogenic and non-amyloidogenic pathways. α and ɣ 
secretases are responsible for the APP cleavage in the non-amyloidogenic pathway and in the amyloidogenic 
pathway β and ɣ secretases are involved. Adapted from (Sumner et al., 2018). 
 
Changes in APP processing such as those linked to PS1 and 2 (components of 
complex of ɣ-secretase complex) are linked to the overproduction of Aβ (Bekris et al., 2010; 
Maloney and Lahiri, 2011). Aβ peptides exhibit 36-43 amino acids that can agglutinate and 
form amyloid aggregates, found primarily in aged neurons (Zuo et al., 2015). In addition, it 
exhibits the ability to self-aggregate in different forms such as oligomers, Aβ40 and Aβ42, 
the more toxic species for cells (Cheignon et al., 2018). The Aβ40 is the most common form 
of Aβ in the brain, but Aβ42 is the most toxic, being considered the primarily Aβ form 
responsible for neuronal damage (Gu and Guo, 2013). Since these oligomers are soluble and 
toxics, their accumulation and aggregation leads to the formation of neuritic or senile plaques 
(Bordon, 2017). The neurodegeneration associated with AD is characterized by loss of 
synaptic function (Magalingam et al., 2018), inflammation and synaptotoxicity (Kocahan 
and Doğan, 2017) that results in gradual neuronal death and memory loss, through the 
interruption of neuronal communication. 
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1.5 The Amyloid Cascade Hypothesis 
The amyloid cascade hypothesis was formulated in 1990s and has become a 
dominant model for AD pathogenesis (Swerdlow, 2007). According to this hypothesis, there 
is an abnormal increase of Aβ levels that leads to Aβ aggregation into β-sheet rich structures 
(Cheignon et al., 2018). The Aβ peptides, which are not degraded by cells, can form 
oligomers and Aβ fibrils, being able to permeabilize the membrane and  represent a primary 
mechanism of amyloid pathogenesis (Glabe, 2006). Thus, Aβ participates or contributes to 
neuronal dysfunction, neurotoxicity, cell death and overproduction of reactive oxygen 
species (ROS) (Zuo et al., 2015). In addition, the oxidative stress may also induce increased 
levels of Aβ and pTau, leading to the onset and progression of AD. 
 
The increase in Aβ42 levels enhances oligomers formation (Figure 5), being 
responsible for local inflammatory responses such as microgliosis and astrocytosis (Frost 
and Li, 2017). Consequently, oxidative stress and neuronal injury lead to synaptic and 
neuritic loss. Those processes culminates with cell death, leading to progressive dementia 
associated with extensive Aβ and Tau pathology (Ricobaraza et al., 2010; Barage and 
Sonawane, 2015). 
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However, in recent years, this hypothesis has been reappraised. The importance of 
Aβ fibrils has been questioned because the number of Aβ plaques is not correlated to the 
severity of disease (Hardy and Selkoe, 2002; Barage and Sonawane, 2015). Aβ plaques are 
also found in healthy humans and with a similar composition, which implies that other 
factors are involved in AD. Therefore, this hypothesis was directed to smaller forms of Aβ 
(Armstrong, 2014), the Aβ oligomers. The oligomers were considered the main causing 
agents for pathological alterations in AD and were associated with neurotoxic activities 
because of the high soluble Aβ concentrations in the brain contributing to neurodegeneration 
in AD (McLean et al., 1999; Serrano-Pozo et al., 2011). However, these oligomers are not 
the only ones that derive from the processing of APP, since other fragments are produced 
during its cleavage by secretases (Figure 4) (Maloney and Lahiri, 2011; Chen et al., 2017). 
Thus, the peptide Aβ may not be the main pathogenic factor of the disease but is, at least, 
involved in its progression. 
 
Figure 5- The amyloid cascade hypothesis. This hypothesis proposes that an abnormal increase of Aβ levels 
leads an accumulation of senile plaques, an initial pathological event in AD. Together with 
hyperphosphorylated Tau exists an increase of accumulation of ROS that starts an inflammatory response, 
resulting in neuronal death and causing AD. Adapted from (Hardy and Selkoe, 2002). 
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2. Oxidative stress and transcriptional changes in Alzheimer’s disease 
 
2.1 ROS and oxidative stress 
ROS play very important roles in cell signalling, cell growth, synthesis of biological 
molecules and stress responses (Zuo et al., 2015). However, high levels of ROS in the cells 
cause modifications on several biomolecules such as proteins, lipids and deoxyribonucleic 
acid (DNA). In normal conditions, there is a constant production of ROS in the cells, 
however, oxidative stress is the result of an imbalance between the formation of ROS and 
their neutralization by the antioxidant defences (Ferreiro et al., 2012; González-Reyes et al., 
2017). Mitochondrial oxidative phosphorylation is the major source of ROS, thus, when 
mitochondrial function is altered, ROS concentrations can be dramatically elevated. Some 
examples of ROS are hydrogen peroxide (H2O2), hydroxyl radical (
OH) and superoxide 
anion (O2
-). The cell has enzymatic and molecular antioxidant defences to cope with the 
ROS production such as superoxide dismutase (SOD), heme oxygenase-1 (HO-1), 
glutathione peroxidase (GPx), glutaredoxins, thioredoxins and catalases (CAT) (Reddy, 
2006). 
 
 
 
 
 
 
 
 
 
 
Figure 6- Formation of ATP and ROS. Mitochondrial electron transport is composed by three complexes: I, 
III and IV, while ATP synthase utilizes the proton motive force to synthesize ATP from ADP. Adapted from 
(Li et al., 2013) 
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Brain has high energy consumption and is highly susceptible to ROS damage. Thus, 
the balance between ROS production and the antioxidant defence system is essential for 
normal cellular function. However, in AD, the increase in oxidative stress accelerates to 
misfolding and aggregation of Aβ and pTau (González-Reyes et al., 2017; Fertan et al., 
2019), causing cellular injuries and mitochondrial dysfunction (González-Reyes et al., 
2017).  
 
2.2 Antioxidant transcriptional factor – Nrf2 
The activation of transcription factors (TFs) have an important role in oxidative stress 
neutralization. The levels of TFs in human postmortem brain and animal models of AD are 
reduced (Caldeira et al., 2013). However, it is unclear whether Aβ directly modulates gene 
expression by altering gene promoters or by interfering with the activity of TFs, in brain 
cells (Shi and Gibson, 2007; Barucker et al., 2014). Importantly, TFs can modulate 
mitochondrial biogenesis and function and the levels of antioxidant enzymes, thus reducing 
the harmful impact of ROS in cells. One of the most important TFs in ROS combat is the 
nuclear factor erythroid 2 related factor 2 (Nrf2) (Bahn and Jo, 2019).  
Nrf2 has a crucial role in stress conditions, mediating the expression of antioxidant 
proteins, detoxifying enzymes and others TFs (Esteras et al., 2016) and contains seven 
conserved domains (Figure 7) (Esteras et al., 2016; Dinkova-Kostova et al., 2018; Bahn and 
Jo, 2019). 
 
 
 
Under basal conditions, Nrf2 is mostly located in cytoplasm where it can bind to 
Kelch-like ECH-associated protein 1 (KEAP1), its endogenous inhibitor, leading to Nrf2 
ubiquitination and degradation by the ubiquitin-proteasome system, which act as an adaptor 
for Cullin-3-based E3 ubiquitin ligase complex (Canning et al., 2015). Following an increase 
Figure 7- Structural domains of Nrf2 protein. Nrf2 protein consists of 605 amino acids and has seven 
homology domains, Neh1–7. The domains of interest in Nrf2 are: Neh2 domain, required for the interaction 
with KEAP1, and a hydrophilic region of lysine residues, which are indispensable for the Keap1-dependent 
polyubiquitination and degradation of Nrf2. Adapted from (Bahn and Jo, 2019). 
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in ROS levels, KEAP1 is oxidized in its cysteine residues, which alters its conformation, 
leading to E3 ubiquitin ligase inhibition and releasing of Nrf2, which then translocate into 
the nucleus (Esteras et al., 2016). Nrf2 mediates the expression of proteins which genes 
contain a cis regulatory element named “antioxidant response element” (ARE). In the 
nucleus, Nrf2 heterodimerizes with Maf proteins and the heterodimers bind to AREs to 
regulate the transcription of Nrf2 target genes, such as SOD1, GPx, CAT and  HO-1 (Figure 
8) (Dinkova-Kostova et al., 2018; Bahn and Jo, 2019).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additionally, it has been shown that phosphorylation of Nrf2 (pNrf2) contributes to 
its nuclear migration (Caldeira et al., 2013), since Nrf2 contains serine, threonine and 
tyrosine residues, which can be sites for phosphorylation by different kinases (Sun et al., 
2009). Phosphorylation of Nrf2 at Ser40 residue by protein kinase C (PKC), impairs its 
association with KEAP1 thus promoting its activation and translocation to the nucleus 
(Figure 8) (Fão et al., 2019). This phosphorylation may be necessary for the dissociation of 
Figure 8- Schematic representation of the Nrf2/Keap1 intracellular pathway. Under normal conditions, 
KEAP1 inhibits Nrf2 signaling pathway, it is ubiquitinated and degraded by the proteasome. In the presence 
of ROS, Nrf2 dissociates from KEAP1, leading to translocation of Nrf2 into nucleus. In these same conditions, 
the Nrf2 phosphorylation by PKC occurs, resulting in Nrf2 nuclear translocation. In the nucleus, Nrf2 promotes 
transcriptional activation of antioxidants and detoxifying enzymes by binding to the ARE in the promoter 
regions of the target genes. Adapted from (Nicoletti et al., 2014) and (Sova and Saso, 2018). 
Effect of class I histone deacetylase inhibitors in 3xTg-AD mice 
 
 
 
14 |  
 
Nrf2 from KEAP1 and for Nrf2 nuclear migration. Taking this into account, Nrf2 has been 
described to be a promising target for therapeutic strategies in the context of 
neurodegeneration because it regulates the expression of cytoprotective and antioxidant 
enzymes. 
 
 
2.2.1 Nrf2 in Alzheimer’s disease 
Some early studies in both human and animal models show that Nrf2 levels in AD 
are decreased  when compared to healthy individuals, suggesting a decrease in Nrf2 activity 
(Vasconcelos et al., 2019). Consequently, some enzymes regulated by Nrf2 have decreased 
activity such as SOD1, glutathione (GSH), CAT (Ansari and Scheff, 2010) and glutathione 
transferase (GST) (Lovell et al., 1998) in human AD cortex, however, the activity of 
NAD(P)H:quinone oxidoreductase 1 (NQO1) (Raina et al., 2004), glutathione reductase 
(GR), GPx (Johnson and Johnson, 2015) and HO-1 (Schipper et al., 1995) is increased, in 
human AD brain. A study of Nrf2 in APP/PS1 animal model showed no differences in NQO1 
and glutamate cysteine ligase (GCLM) messenger ribonucleic acid (mRNA) levels but a 
decrease in GCLM and NQO1 expression at 6 months-old and a reduction in Nrf2 levels at 
16 months of age (Kanninen et al., 2008). More recently, APP/PS1 mice at 7-8 months-old 
showed increased levels of OH-1 and GPx, however mRNA levels of GCLM and NQO1 
were not altered (Joshi et al., 2015). Concordantly, the triple transgenic animal model of AD 
(3xTg-AD )animal model showed increased NQO1 and augmented Nrf2 and SOD protein 
levels in both hippocampus and cortex, at 2 months and 3 months of age, respectively (Mota 
et al., 2015). Conversely, decreased SOD1 and HO-1 mRNA were also found at 3 months 
of age. However, at 6 and 15 months-old, this model showed reduced NQO1 and Nrf2 levels 
in the hippocampus (Torres-Lista et al., 2014) (Mota et al., 2015). Additionally, some studies 
show that at 3-month-old 3xTg-AD mice, Nrf2 phosphorylation levels at Ser40 are increased 
in peripheral blood mononuclear cells (PBMCs) and the nuclear levels of Nrf2 are decreased 
in the brain cortex. Accordingly, an increase in oxidative stress levels, as well as 
phosphorylation of Nrf2, were found in PBMCs of humans with MCI (Mota et al., 2015). 
However, in both 3xTg-AD mice and human PBMCs, it was found that SOD1 protein levels 
were decreased, suggesting a failure in the regulation of Nrf2 target genes in AD. 
These distinct results may be explained by different levels of Nrf2 at different stages of the 
disease and the type of tissue collected for the study, perhaps indicative of a positive 
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regulation of antioxidant defenses to combat oxidative stress in the early stages of AD, 
whereas the loss of antioxidant enzyme activity as well as the Nrf2/ARE pathway may be 
more evident in the later stages of the disease (Sun et al., 2017). 
 
3. The triple transgenic Alzheimer’s disease mouse model 
 
There are several transgenic animal models of AD that mimic some of the hallmarks 
described in human patients and that are used in research for understanding the disease 
mechanisms and development of therapeutic treatments. The triple transgenic AD mouse 
model (3xTg-AD) (Figure 9) exhibits the behavioural and neuropathological (neuritic 
plaques and neurofibrillary tangles) changes that are observed in AD patients (Oddo et al., 
2003). 
 
Figure 9- 3xTg-AD mouse model. Taken from https://www.jax.org/strain/004807 
 
The 3xTg-AD mouse was first described by Oddo et al. (2003). It expresses three 
human mutant genes: PS1M146V, APPK670N/M671L (also named APPSwe), and TauP301L (Figure 
10). This transgenic line was created by microinjection of two transgenes: APPSwe and 
TauP301L into single-cells from homozygous PS1M146V knock-in mice.  
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In this mouse model, intraneuronal Aβ plaques appear first between 3 and 4 months 
of age in the neocortex and by 6 months of age in hippocampal CA1 pyramidal neurons. 
Extracellular deposits of Aβ first appear in 6 months-old mice in the frontal cortex and 
expand to the hippocampus at 12 months of age. Tau pathology appears after 12 months of 
age, particularly in hippocampal neurons. 
In general, 3xTg-AD mice demonstrated decrease exploratory activity and higher 
anxiety levels and depression such as in AD human (Stover et al., 2015; Huber et al., 2018). 
According to the behavioural and cognitive characterization performed by Sterniczuk, 3xTg-
AD females between 7.5 and 11 months of age presented high levels of anxiety (Sterniczuk 
et al., 2010b) and depression. In this model, there is a rapid decline in cognitive ability, the 
capacity of learning and memory is also affected.  
 
4. Protein acetylation and epigenetic alterations in Alzheimer’s disease 
4.1 Epigenetic alterations and transcription regulation 
Epigenetic changes consist in altering the expression of genes without affecting the 
DNA sequence, as a result of environmental stimuli, growth or development (Zuo et al., 
2015). Epigenetic alterations can be described as three main mechanisms: DNA methylation, 
histone modifications and microRNA (miRNA) activity. DNA methylation can be described 
as the addition of a methyl (CH3) group by DNA methyltransferase (DNMT) enzyme to the 
cytosines that precede the guanines, inactivating transcription by preventing the binding of 
TFs (Yin et al., 2017). Histone modifications involve acetylation, methylation, 
phosphorylation or ubiquitylation of histones. In histone modification, chromatin 
remodelling was identified as the major epigenetic mechanism because this modification has 
Figure 10- Strategy used to develop the 3xTg-AD mice. Adapted from (Oddo et al., 2003). 
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important roles in transcriptional regulation (Gräff et al., 2011; Sanchez-Mut and Gräff, 
2015). miRNAs are the most studied group of noncoding RNAs and are negative regulators 
of gene expression at the posttranscriptional level (Qiu et al., 2015; Cao et al., 2018). These 
regulate different physiological functions such as growth, development and cellular 
homeostasis. About 70% of miRNAs have been detected in the brain (Sharma and Lu, 2018) 
and therefore have a high importance in synaptic development, neuroplasticity as well as in 
the formation and maturation of synapses. Curiously, miRNA expression is altered in AD 
(Qiu et al., 2015). 
The nervous system is a highly specialized system where cells are organized in 
different sub-structures, with different epigenetic profiles (Cao et al., 2006). Thus, neuronal 
activity and brain function are regulated by a dynamic modulation of chromatin and gene 
expression profiles, namely after histone post-translational modifications (PTM).  
 
4.2 Histone modifications – acetylation vs. deacetylation 
Histones are the most abundant proteins associated with DNA and their acetylation 
is the most studied modification. It involves the transfer of an acetyl group from acetyl 
coenzyme A to lysine residues at the histone tails (Zovkic et al., 2013) by histone 
acetyltransferases (HAT), while histone deacetylases (HDAC) act to remove acetyl groups 
(Figure 11) (Delcuve et al., 2012; Sanchez-Mut and Gräff, 2015). In normal neurons, the 
protein levels of HAT and HDAC and their activities are kept in a balanced state, hence 
regulating normal gene expression (Xu et al., 2011). Recent studies suggest that the decrease 
in histone acetylation is associated with an increased compaction of chromatin (Zwergel et 
al., 2016) since the positive charge of modified histone protein, due to the amine group of 
its composition, facilitates interactions with negatively charged DNA and promotes 
condensed chromatin states, thereby repressing gene transcription (Sanchez-Mut and Gräff, 
2015). 
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HDACs are divided into three zinc-dependent classes: class I, class II and class IV. 
There is also class III, which is dependent on nicotinamide adenine dinucleotide (NAD+), as 
the sirtuins (Gräff et al., 2011). The zinc-dependent classes present different HDACs, as 
reported in Table 2. 
 
Table 2- Classes of zinc-dependent HDACs and their preferential localization. 
 Nucleus Cytoplasm 
Class I 1, 2, 3 and 8 - 
Class IIa 4, 5, 7 and 9 4, 5, 7 and 9 
Class IIb - 6 and 10 
Class IV 11 - 
 
Histone acetylation occurs in the hippocampus in response to contextual learning 
(Levenson et al., 2004), however, this acetylation is disturbed in neurodegenerative states, 
because the levels of HAT activity are reduced (Pirooznia and Elefant, 2013). Previous 
studies (Ferrante et al., 2003; Fischer et al., 2007; Ricobaraza et al., 2009; Cao et al., 2018) 
aimed to characterize chromatin modifications in AD and they were mainly focused on 
HDACs, which when inhibited showed neuroprotective effects in AD animal models.  
 
4.2.1 Class I of HDACs 
Class I of HDACs consists of HDACs 1, 2, 3, and 8, which are mainly localized in 
the nucleus, where they regulate histone acetylation, HDAC8 is generally poorly expressed 
(Alaghband et al., 2017). The levels of HDAC1 mRNA were also lower when compared 
Figure 11- Modifications of histones by HATs and HDACs. HATs transfer acetyl groups to lysine residues 
of histones and gene transcription is activated, whereas HDACs remove acetyl groups from histones and gene 
transcription is inactivated. Adapted from (Schneider et al., 2013). 
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with HDACs 2 and 3. Recent studies indicate that the activity of specific class I enzymes 
may be altered in psychiatric diseases and may play a role in the effective treatment (Xu et 
al., 2011). According to Guan and colleagues, the inhibition of HDAC2 results in an increase 
in synaptic plasticity, number of synapses and memory formation (Guan et al., 2009). Thus, 
they claim that this is a negative regulator of memory formation and syntactic plasticity 
(Gräff et al., 2011; Xu et al., 2011). HDAC1 and HDAC2 exhibit a degree of homology 
(Delcuve et al., 2012), however, the role of HDAC1 in memory is opposite to that of HDAC2 
(Bahari-Javan et al., 2014). When HDAC3 levels are inhibited this enzyme has the ability to 
restore the synaptic plasticity induced by oligomers of A in neurons (Krishna et al., 2016), 
so HDAC3 plays a negative role in memory formation. As HDCA8 is poorly expressed, 
information regarding its role in memory formation or neural plasticity is scarce (Delcuve et 
al., 2012). 
 
4.3 Histone deacetylases inhibitors and their treatment in Alzheimer’s disease 
The HDAC inhibitor (HDACi) can be classified into different classes: fatty acids 
[sodium butyrate (SB), phenylbutyrate (PB) and valproic acid (VPA)]; hydroxamic acids 
[(trichostatin A (TSA) and SAHA)]; mercaptoketone (KD5170), cyclic peptides and 
benzamides [(tacedinaline (CI-994) and MS-275] (Tandon et al., 2016). Amongst these, the 
most widely studied are SB, PB, VPA, TSA and SAHA, a pan inhibitor of HDACs. In 
contrast, SB, PB and KD510 are selective to classes I and IIa HDAC (Fessler et al., 2013; 
Tandon et al., 2016). For class I HDACs, the inhibitors with better selectivity are MS-275,  
CI-994 and, finally TSA, which was the first discovered to inhibit HDACs (Yoshida et al., 
1990), namely by inhibiting the activity of classes I and II HDACs.  
 
Inhibition of  class I HDAC isoforms simultaneously could be a promising therapy 
for improving transcriptional levels, promoting synapse formation and ameliorating 
cognition (Yang et al., 2017). These inhibitors are potential treatment for AD due to their 
effect on decrease of Aβ levels (Xu et al., 2011). In 2003, Hockly and colleagues showed 
that Varinostat (SAHA), an HDACi led to increased levels of histone acetylation when 
administered orally in drinking water, in the R62 mice model of HD (Hockly et al., 2003). 
With this, they have showed that HDACis can be used as a possible treatment strategy in 
neurodegenerative diseases and identified a neuroprotective mechanism that includes the 
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regulation of histone acetylation homeostasis. The HDACis increase the acetylation levels 
of histones by reducing deacetylation, subsequently upregulating gene transcription, and also 
enhance hippocampus dependent memory formation (Levenson et al., 2004; Guan et al., 
2009; Zwergel et al., 2016). 
It was demonstrated that HDACis are able to decrease Aβ levels in transgenic mice 
by targeting genes required for Aβ formation. For example, the use of VPA reduces Aβ 
plaques and restores memory in APP23 mice model (Qing et al., 2008). Similarly, SAHA 
was shown to rescue contextual memory in APP/PS1 model, to cross the blood-brain barrier 
(BBB) and to increase H4 acetylation in the brain (Kilgore et al., 2010). Moreover, the 
administration of MS-275 in the APP/PS1 mouse model caused a decrease in Aβ deposition 
and attenuated inflammatory (Zhang and Schluesener, 2013). Administration of the 4-
phenylbutyrate (PBA) inhibitor in the animal model Tg2576 of AD (duration of 5 weeks) 
with 6 and 12-16 months, led to the restoration of memory as well as learning capacity 
(Ricobaraza et al., 2010). In addition, administration of SB intraperitoneally for 6 weeks in 
the 15-month APP/PS1-21 animal model allowed for memory restoration, increased 
expression of genes associated with learning as well as to the increase of histone acetylation 
(Govindarajan et al., 2011). The study of Zhang and colleagues,  showed that MS-275 
administered orally in APP/PS1 mice  model for 10 days, led to a decrease in Aβ deposition 
in the cortex as well as in the hippocampus (Zhang and Schluesener, 2013). More recently, 
in YAC128 model of Hungtinton’s disease (HD), the administration of SB (1 mg/kg/day) 
through mini-osmotic pumps, led to an increase in histone acetylation levels (Naia et al., 
2017). These results suggest that, when used at low concentrations/doses, HDACis may 
constitute a therapeutic option in AD as well as in other neurodegenerative diseases since 
they are expected to have beneficial neuroprotective effects. More recently, in 2018, it has 
been shown by Janczura and colleagues that oral administration of RGFP-966, an inhibitor 
of HDAC3, led to decreased Aβ42 protein levels in the brain in the 3xTg-AD mouse model 
(Janczura et al., 2018).  
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In addition to these HDACis, previous studies with SB demonstrated neuroprotective 
effects, ameliorated oxidative stress and inflammation, and improved memory deficits in a 
mouse model of cerebral ischaemia (Sun et al., 2015). Furthermore, a prolonged treatment 
with SB also improved memory in APP/PS1 mice even in advanced stages of pathology, and 
increased the expression of genes implicated in learning (Govindarajan et al., 2011). 
Moreover,  class I HDACis such as SB elevated histone H4 acetylation and restored 
contextual memory in the APP/PS1 mice model of AD (Kilgore et al., 2010; Xu et al., 2011). 
Therefore, increasing histone acetylation to ameliorate memory in the context of AD may 
be a promising therapeutic strategy. 
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CHAPTER II- Objectives 
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The presence of Aβ and intracellular neurofibrillary tangles constitute pathological 
hallmarks of AD. The balance between acetylation of histones by HAT and HDAC 
represents a central mechanism in regulation of gene expression (Xu et al., 2011).  
Deregulation of histone acetylation has been implicated in the onset of age-associated 
memory impairment and AD pathogenesis because the reduction in histone acetylation levels 
promotes amnesia and interferes with the consolidation of memories (Bahari-Javan et al., 
2014). Moreover, the levels of Nrf2 are altered in this disease. The levels of histone 
acetylation is possible to modulate with specific HDACis (Cao et al., 2018). 
Considering that AD has been characterized by impaired memory, cognition and 
personality, decreased acetylation of histones due to lower HAT and altered levels of Nrf2, 
the main aims of this work are: 
 
I) To determine the impact of sodium butyrate on behavior profile of 3xTg-AD 
mice  
In this study, 3xTg-AD mice with 10.5 months of age will be subjected to different 
behavioral tests for analysis of anxiety, cognition and memory in order to evaluate if 
treatment with the HDACi sodium butyrate (SB) affects these AD-related behaviors in 3xTg-
AD, compared to untreated/saline-treated 3xTg-AD and wild-type (WT) mice; 
 
II) To evaluate the influence of sodium butyrate on histone acetylation in the 
brain cortex of 3xTg-AD mice  
 The activity of histones can be controlled by inhibitors of HDACs. Therefore, we 
will evaluate the acetylation levels of H3 histone after treatment of 3xTg-AD mice with SB, 
compared to untreated/saline-treated 3xTg-AD and WT mice; 
 
III) To examine the changes in Tau protein levels and phosphorylation, and 
protein levels of ROS-related transcription factor Nrf2 and phosphorylation following 
SB treatment in the brain cortex of 3xTg-AD mice 
 We will determine the levels of Nrf2 and pNrf2 in 10.5 months-old 3xTg-AD mice 
brain treated with SB, compared to untreated/saline-treated 3xTg-AD and WT mice.  
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CHAPTER III- Material and methods 
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3.1 Material 
All materials and reagents were of the highest grade of purity commercially available. 
Sodium butyrate (SB), protease inhibitor cocktail, hydrogen peroxide (H2O2) and goat serum 
were from Sigma Aldrich (St Louis, Missouri). Mini-osmotic pumps were from Alzet 
(Durect Cop., Cupertino, California). Sodium pentobarbital was from Nephar - Farma lda, 
(Mem Martins – Portugal) and buprenorphine was from Laboratórios Karizoo, S.A. (Caldes 
de Montbui – Espanha). Fatty acid-free bovine serum albumin (BSA) used in Western 
Blotting was purchased from NZYtech (Lisbon, Portugal). BioRad Protein Assay was 
purchased from BioRad Laboratories, Inc. (Munich, Germany), Western Blot Immobilon-℗ 
PVDF membrane, and phenylhydrazine and Triton-X100 used in immunohistochemistry 
were from Merck Millipore (Darmstadt, Germany). Tissue-Tek optimum cutting 
temperature (O.C.T.) cryostat sectioning medium was from Sakura Finetek (United 
Kingdom). Toluene-based Richard-Allan Scientific Mounting Medium and DPX Mounting 
Medium were from Thermo Scientific (Waltham, Massachusetts, EUA). Hoechst 33342 
nucleic acid stain was purchased from Invitrogen/Molecular Probes (Life Technologies 
Corporation, Carlsbad, CA, USA). Cryostat-microtome Leica CM3050S was from Leica 
Microsystems Nu (Wetzlar, Germany) and microscope Zeiss Axio Imager Z2 microscope 
were from Zeiss (Oberkochen, Germany). All the primary antibodies used for Western 
Blotting and immunohistochemistry are described in Table 2 and Table 4, respectively. 
 
Table 3- Antibodies used for Western Blotting analyses. 
Primary antibodies Host Dilution Reference 
Tau-5 Mouse 
1-2 
µg/mL 
Abcam (#ab80579) 
Phospho-Tau (T231) Rabbit 1:5000 Abcam (#ab151559) 
Acetyl-H3 Rabbit 1:500 Millipore (#06-599) 
H3 total Rabbit 1:2000 
Cell Signaling Technology 
(#9715) 
β-actin Mouse 1:5000 Sigma (#A5316) 
Phospho-Tau (Ser416) Rabbit 1:1000 Cell signalling (#15013T) 
Nrf2 Rabbit 1:500 Abcam (#ab31163) 
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Secondary antibodies    
Anti-Rabbit (H+L), 
Alkaline Phosphatase 
conjugated 
Goat  1:10000 
Pierce Thermo Fisher Scientific 
(#31340) 
 
Anti-Mouse (H+L), 
Alkaline Phosphatase 
conjugated 
Goat 1:10000 
Pierce Thermo Fisher Scientific 
(#31320) 
 
Table 4- Antibodies used for Immunohistochemistry analyses. 
Primary antibodies Host Dilution Reference 
6E10 Mouse 1:2000 Covance (New Jersey, USA) 
AT-8 Mouse 1:2000 Pierce (#MN1020) 
Aβ42 Mouse 1:1000 Chemicon Millipore Merck 
APP Rabbit 1:1000 Abcam (Cambridge, UK) 
Secondary antibody    
Universal antibody Horse 1:200 
Vectastain Elite ABC kit, 
Vector Laboratories 
Alexa Fluor 594® Goat 1:1000 
Molecular Probes - Invitrogen 
(Eugene, OR, USA) 
Alexa Fluor 488® Goat 1:1000 
Molecular Probes - Invitrogen 
(Eugene, OR, USA) 
 
 
3.2 Methods 
3.2.1 Animals 
Research was conducted in compliance with EU and Portuguese directives regarding 
the use of laboratory animals (EU Directive 2010/63/EU and Portuguese law DL113/2013, 
August 7th). All procedures were approved by the local Animal Welfare Committee of the 
Center for Neuroscience and Cell Biology and Faculty of Medicine, University of Coimbra 
(ORBEA) and the Portuguese National Authority for Animal Health (DGAV) (ethical permit 
#211). Animals were housed at our local animal facilities (conventional animal facilities of 
the Center for Neuroscience and Cell Biology and Faculty of Medicine, University of 
Coimbra, Coimbra, Portugal), in groups of 3-4 mice per static microisolator cage with a filter 
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top, and bedding and nesting materials, under controlled temperature (22 º C), humidity (45-
65 %) and light conditions (12 h day/night cycle, with lights on at 6 a.m.). Standard hard 
pellets chow and sterilized and acidified water (pH 2.5-3) were available ad libitum 
throughout the experiment. Signs of distress were carefully monitored and all efforts were 
made to minimize animal suffering and to reduce the number of animals used. Although not 
expected, a rapid decrease of body weight (>15-20%) was considered as a humane endpoint 
for the study.  
 
3.2.2 Genotyping  
3xTg-AD and wild-type (WT) mice were genotyped using a DNA polymerase chain 
reaction (PCR) standard procedure with DNA extracted from an ear punch, by using PS1 
forward (CAC ACG CAA CTC TGA CAT GCA CAG GC), PS1 reverse (AGG CAG GAA 
GAT CAC GTG TTC AAG TAC), APP forward (GCT TGC ACC AGT TCT GGA TGG), 
APP reverse (GAG GTA TTC AGT CAT GTG CT), Tau forward (GAG GTA TTC AGT 
CAT GTG CT) and Tau reverse (TTC AAA GTT CAC CTG ATA GT) primers. For the PS1 
gene, the PCR protocol consisted of 35 cycles of denaturation - 94 ºC for 40 s; annealing - 
62 °C for 40 s and elongation - 72 °C for 1 min. For the APP gene, the PCR protocol 
consisted of 20 cycles of denaturation – 94 ºC for 30 s; annealing – 53 ºC for 30 s and 
elongation – 72 ºC for 1 min. For the Tau gene, the PCR protocol consisted of 25 cycles of 
denaturation – 94 ºC for 30 s; annealing – 52 ºC for 30 s and elongation – 72 ºC for 3 min. 
PCR products were analysed on 1.7 % agarose gels followed by staining with GreenSafe 
(NZYtech, Lisboa, Portugal) at 150 V for 30 min with Tris-acetate-EDTA running buffer 
and visualized under a UV transilluminator (Gel Doc XR system BioRad®, Hercules, USA). 
 
Animals of both genders were subjected to genotyping analysis, but we only use male 
mice in our studies. Genotypic analysis indicates the presence of human APP (Figure 12A), 
Tau (Figure 12B), and PS1 (Figure 12C) transgenes in the 3xTg-AD compared to WT mice. 
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3.2.3 Mouse mini-osmotic pump implantation surgery and treatment 
Twenty-eight 3xTg-AD male mice and twelve age-matched WT male mice were 
subjected to the subcutaneous implantation of Alzet mini osmotic pumps (model 2006), 
previously filled with either sterile saline (0.9 % NaCl) or sodium butyrate (SB: 1 mg/kg/day, 
diluted in sterile saline solution) and primed in sterile saline at 37 ºC for at least 72 h before 
implantation, according to manufacturer’s instructions. Prior to the surgery, mice were 
submitted to analgesia with subcutaneous buprenorphine (0.10 mg/kg) injection for thirty 
minutes (starting at 6:30 a.m.), followed by anesthesia with continuous isofluorane 
inhalation (4-5 % during the induction of sedation and then 1.5-2 % for maintenance) during 
the overall surgical procedure. Then, a small incision was made in the skin between the 
scapulae and, with the aid of a hemostat, a small pocket was formed by spreading apart the 
subcutaneous connective tissues to insert the mini osmotic pump subcutaneously, with the 
flow moderator pointing away from the incision. The skin incision was then closed with 
surgical clips. After recovery from anaesthesia, mice were returned to their cage, provided 
with wet food and water, carefully monitored and administered with post-surgical 
buprenorphine analgesia (0.05 mg/kg) every 6 h, for at least 24 h. According to the 
Figure 12- Characterization of experimental animals by genotyping analysis. Representative genotyping 
data of ear tissue from WT and 3xTg-AD mice male. These results show the presence of APP gene (A), TAU 
gene (B) and PS1 (C) human genes in 3xTg-AD compared to WT mice. 
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manufacturer, the content of the mini osmotic pumps was continuously delivered at a flow 
rate of 0.15 µL/hour, for 42 days. Body weight was measured before, during (once a week) 
and after treatment. 
3.2.4 Behavioural analyses 
 From the 39th until the 42nd day of treatment, mice transferred to the behavior room 
on the day before the beginning of behavioral tests to be accustomed to its environment, 
where they were subjected to several behavioural tests to evaluate their exploratory activity, 
anxiety and short-term spatial memory. Behavioural tests were performed every day between 
7:00 a.m. and 12:00 p.m., for 4 consecutive days, in a silent room, under dim light and with 
the aid of an experienced observer blind to the experimental conditions. Tests were 
performed in the following order: Y-maze, open field (OF), object displacement (OD) and 
novel object recognition (NOR) tests. During this period, mice were maintained in standard 
housing conditions. Of note, for every behavioral test, the platform was always cleaned with 
10 % ethanol between each animal housed in the same cage and 70 % ethanol between 
animals of different cages. All experiments were continuously recorded by the computer-
operated video ANY-MAZE video tracking system and respective software (Stoelting Co., 
Wood Dale, IL, USA). 
 
3.2.4.1 Modified Y-maze test 
The modified Y-maze test is a short-term recognition spatial memory test, based on 
the innate preference of animals to explore areas that have not been previously explored 
(Soares et al., 2013). It was performed in a Y-shaped plexiglass apparatus consisting of three 
identical arms (35 cm long, 5 cm wide and 10 cm high), separated by angles of 120º: the 
Start arm, whereby the animal is placed at the start of the experiment and is always opened; 
the Other arm, that is opposite to the start arm and also always open; and the Novel arm, that 
is blocked during the training phase, being opened only during the test phase. During the 
training session, the mice were allowed to freely explore the Start and the Other arm for 8 
min, whereas the Novel arm was blocked (Dellu et al., 1992, 1997; Akwa et al., 2002). After 
a 120-min inter-trial interval, animals were subjected to the test session, after the removal of 
the wall that blocked the Novel arm and its opening for free exploration of the three arms 
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for 8 min (Figure 13). Memory performance was given by the percentage of time spent in 
the novel arm over the time spent exploring all arms.  
 
 
 
 
 
 
 
 
3.2.4.2. Open field test  
 The Open field behavior test allows the assessment of the locomotor and 
behavioral activity (namely anxiety-like behavior) in rodents (Gould et al., 2009). Motor 
activity was evaluated in an open field squared arena with grey open-topped boxes (38 cm 
wide ×38 cm), using the Stoelting ANY-MAZE video tracking system and respective 
software to detect the position of the animal’s head (Figure 14). Mice were placed 
individually at the corner of the open field arena and allowed to move freely for 10 min. 
Their exploratory activity within the center and peripheral areas was tracked, and data was 
calculated by the Any-Maze software. 
 
 
 
 
 
 
Figure 13- Schematic representation of the modified Y-maze behavioural test. The training phase lasted 
for 8 min and the mice were allowed to freely explore the Start and Other arm of the maze. After a 120 min 
inter-trial interval, animals were allowed to explore all three arms for further 8 min. 
Figure 14- Schematic representation of the open field arena. Animals are allowed to move freely in the 
arena for 10 min, and their behaviour was monitored. The inner square represents the center of the arena. 
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3.2.4.3. Object displacement test  
 The apparatus used for the Object Displacement test consisted of a plexiglass dark 
grey square arena measuring 38×38 cm. During the first 10 min, mice were allowed to move 
freely in the arena for habituation. Then, during the acquisition phase the animals were 
allowed to freely explore two identical tall soda cans placed within the arena for further 10 
min. These objects were heavy and big enough to prevent mice from moving or climbing 
them during the trial sessions. After a 90-min inter-trial interval, one of the objects was 
moved to the opposite place in the arena and mice were allowed to freely explore the objects 
for other 5 min (test session) (Figure 15). Data regarding their exploratory activity was 
tracked and calculated by the Any-Maze software and presented as 
Time spent exploring the displaced object 
Time spent exploring the displaced object+Time spent exploring the non−displaced object 
×100. 
 
 
 
 
 
 
Figure 15- Schematic representation of the object displacement behavioural test. The habituation phase 
lasted 10 min, during which the mice were allowed to freely explore and become familiar to the arena. Then, 
during the training phase mice were allowed to freely explore the arena containing two identical tall soda cans 
for further 10 min. After a 90 min inter-trial interval, one of the objects was moved to its opposite place in the 
arena and animals were allowed to freely explore the objects for plus 5 min (test phase). 
 
3.2.4.4. Novel object recognition test  
 The apparatus used for the Novel Object Recognition consisted of a dark grey 
square arena measuring 38×38 cm (Figure 16). During the first 10 min, mice were allowed 
to move freely in the arena for habituation. Then, during the acquisition phase the animals 
were allowed to freely explore two identical tall soda cans placed within the arena for plus 
10 min. These objects were heavy and big enough to prevent the animals from moving or 
climbing them during the trial sessions. After a 90-min inter-trial interval, one of the cans 
was replaced by a novel object (a plastic ketchup bottle), but kept in the same position, and 
the animals were allowed to freely explore the objects for further 5 min. Data regarding their 
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exploratory activity was tracked and calculated by the Any-Maze software and presented as 
Time spent exploring the novel object
Time spent exploring the novel object+Time spent exploring the familiar object 
×100. 
 
 
 
 
 
 
 
 
 
3.2.5 Brain tissue preparation for immunohistochemical analysis 
Mice were deeply anesthetized with sodium pentobarbital (70 mg/kg i.p.) and 
perfused transcardially with 0.9 % NaCl, for 14 min, followed by perfusion with 4% 
paraformaldehyde (4% PFA) in phosphate buffered solution (PBS), containing (in mM): 137 
NaCl, 2.7 KCl, 1.8 KH2PO4, 10 Na2HPO4·2H2O, pH 7.4), for further 30 min. The brain was 
removed and post-fixed in a glass vial with 4 % PFA in PBS for further 24 h, at 4 ºC. Then, 
fixed brains were rinsed twice with PBS and cryoprotected by immersion in 20 % (w/v) 
sucrose prepared in PBS, at 4 ºC, until it sank in the bottom of the vial. The brain was then 
snap frozen in liquid nitrogen and kept at -80 ºC until cryostat sectioning.  
 
3.2.6 Preparation of protein extracts from brain homogenates 
Animals were euthanized by cervical displacement, the brains were collected, the 
cortex, hippocampus and cerebellum immediately dissected on ice (~4°C) and kept at -80°C 
until further use for homogenization and preparation of total protein extracts. For these, the 
previously dissected tissues were homogenized with RIPA lysis buffer (composed by 150 
mM NaCl, 50 mM Tris, 5 mM EGTA, 1% Triton X-100, 0.5% deoxycholate, 0.1% sodium 
dodecylsulphate (SDS), pH 7.5), supplemented with 1 mM dithiotreitol (DTT), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), plus 1µg/ml protease inhibitor cocktail (containing 
chymostatin, pepstatin A, leupeptin and antipain), 100 nM okadaic acid, 25 mM sodium 
Figure 16- Schematic representation of the novel object recognition behavioural test. The habituation 
phase lasted 10 min, during which the mice were allowed to freely explore and become familiar to the arena. 
Then, during the training phase mice allowed to freely explore the arena containing two equal objects for plus 
10 min. After a 90 min inter-trial interval, one of the object was replaced by a novel one (plastic ketchup bottle) 
placed in the same position and the animals allowed to freely explore the objects for plus 5 min (test phase). 
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fluoride (NaF), 1 mM sodium orthovanadate (Na3VO4) and 1 µM Trichostatin A (TSA) (a 
HDACi). The extracts were centrifuged at 3000 xg, in an Eppendorf 5417R centrifuge, for 
15 min, at 4 ºC. The obtained pellet was discarded, and the protein concentration of the 
supernatant was determined using the Bio-Rad protein assay, following the manufacturer’s 
instructions. Extracts were stored at -20 °C until further use. 
 
3.2.7 Western blotting 
Equivalent amounts of protein extracts (10-30 μg) were denatured with 6x 
concentrated loading buffer (containing 300 mM Tris-HCl (pH 6.8), 12 % SDS, 30 % 
glycerol, 600 mM DTT, 0.06 % bromophenol blue), at 70 °C, for 10 min, and 20-30 µL of 
each were loaded and separated by SDS-PAGE (7-15 %). Then, proteins were 
electrophoresed onto polyvinylidene difluoride (PVDF) membranes. The membranes were 
blocked with 5 % (w/v) BSA in Tris buffered saline (containing 25 mM Tris-HCl and NaCl 
150 mM, pH 7.6) with 0.1 % Tween-20 (TBS-T), for 1h at room temperature (RT) and then 
incubated overnight at 4 °C with the primary antibodies. After washing the membranes 3 
times in TBS-T for 15 min each, anti-mouse or anti-rabbit secondary antibody conjugated to 
alkaline phosphatase prepared in 1 % (w/v) BSA in TBS-T were applied for 1 h at RT and 
excess antibody washed 3 times, 15 min with TBS-T. Immunoreactive bands were visualized 
by alkaline phosphatase activity after incubation with ECF reagent, visualized using a 
BioRad ChemiDoc Touch Imaging System (BioRad, Hercules, USA) and quantified using 
Image Lab analysis software (BioRad). All the primary and secondary antibodies, respective 
dilutions and commercial references are described in Table 3. 
 
3.2.8 Immunohistochemistry analysis 
Brains collected for immunohistochemistry studies (as detailed elsewhere) were 
included in Tissue-Tek optimum cutting temperature (O.C.T.) compound and then sectioned 
into 40 μm-thick coronal sections using a Leica CM3050S cryostat-microtome. Slices were 
collected in four series and stored in 48-well plates with sterile 0.1 M PBS, supplemented 
with 0.05 % (v/v) sodium azide, and stored at 4 °C until further use. 
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 3.2.8.1 DAB immunohistochemistry 
For immunostaining, slices were rinsed with PBS at RT for 15 minutes with mild 
agitation. For colorimetric assays (Belfiore et al., 2019), slices were incubated with 
phenylhydrazine in 1x PBS (1:1000) for 30 min, at 37 ºC. Slices were then rinsed 3 times, 
10 min each, with PBS, and blocked in a blocking solution prepared with 10 % goat serum 
plus 0.2 % Triton X-100 in PBS, for 1h, at RT. Then, slices were incubated with primary 
antibodies (previously prepared in blocking solution), overnight, at 4 ºC with mild agitation. 
Slices were then rinsed again 3 times, 10 min each, with PBS and incubated for 1 h at RT 
with the universal secondary antibody, prepared in blocking solution. Slices were rinsed 3 
times, 10 min each, with PBS and then incubated with avidin–biotin complex (ABC, from 
Vectastain), for 1 h, at RT. Slices were then rinsed twice for 10 min each with PBS and 
incubated with diaminobenzidine (DAB) for 2-4 min, at RT. Finally, the slices were rinsed 
3 times, 10 min each with PBS, mounted on gelatinized glass slides and allowed to dry for 
15 min at 37 ºC. Afterwards, tissue sections were progressively dehydrated in 70 % ethanol 
for 5 min, followed by 95 % ethanol for 5 min, 100 % ethanol for 5 min and, finally, with 
xylene for 3 times, 2 min each. As a final step Richard-Allan Scientific Mounting Medium 
was applied and sections covered with glass coverslips and allowed to dry. Immunostainings 
were visualized on a Zeiss Axio Imager Z2 microscope (Zeiss) using Plan-Apochromat 5x 
and 10x/0.8 M27 objectives. All primary and secondary antibodies are described in Table 
4. 
 
3.2.8.1 Fluorescent immunohistochemistry 
For immunostaining, slices were rinsed 3 x 10 min with PBS at RT with mild 
agitation. The slices were incubated with blocking solution of PBS with 3% BSA and 0.2% 
Triton X-100 for 1 h at RT. Slices were the rinsed 3 x 10 min with PBS, blocked in a blocking 
solution of 3% BSA and 0.2% Triton X-100 in PBS, during 1 h at RT and incubated with 
primary antibodies prepared in blocking solution ON, at 4 ºC with mild agitation. Slices were 
then rinsed 3 x 10 min with PBS and incubated for 2 h at RT with the secondary antibody 
and Hoechst 33342 prepared in blocking solution. Slices were rinsed 3 x 10 min with PBS 
and mounted on gelatinized glass slides with DPX mounting medium and allowed to dry. 
Immunostainings were visualized on a Zeiss Axio Imager Z2 microscope (Zeiss) using Plan-
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Apochromat 5x, 10x and 20x/0.8 M27 objectives. All primary and secondary antibodies are 
described in Table 4. 
 
3.2.9 Statistical analysis 
Results were presented as scatter plot with bar, with mean ± standard error of the 
mean (S.E.M.) of the indicated number of mice/group. Statistical analysis and graphic 
artwork were obtained using the GraphPad Prism 7.0 software (GraphPad Software, San 
Diego, CA, USA). After the identification of outliers with the ROUT test and after the 
Kolmogorov-Smirnov normality test, statistical significance was determined by the 
Student’s t-test for comparison between two cohorts with a Gaussian distribution, by one-
way ANOVA test followed by the Sidak post-hoc test for multiple groups with a Gaussian 
distribution, or by the Kruskal-Wallis test (for a non-Gaussian distribution) followed by 
Dunn’s post-test. A p value <0.05 was considered statistically significant: *p <0.05, **p 
<0.01 and ***p <0.001. 
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4.1 Analysis of body weight in 3xTg-AD mice 
 
 
To evaluate if sodium-butyrate (SB) administration affects mouse body weight, this 
parameter was measured before, during and after treatment with SB. Before implantation of 
mini osmotic pumps, the 3xTg-AD mice present a small, but statistically significant 
difference in body weight when compared to WT mice (30.62 ± 0.3019 g, n= 25 for 3xTg-
AD vs 29.11 ± 1.136 g, n= 10 for WT; p*** < 0.001, by the Student’s t-test; Figure 17A). 
During the treatment, the animals did not suffer significant weight changes until they were 
moved to the behavior test room (Figure 17B), when they presented a tendency, although 
not significant, for a decrease in body weight during the time they were subjected to the 
behavioral tests. In general, the body weight is increased in 3xTg-AD animals before, during 
and after the treatment.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17- Body weight one day before mini-pumps implantation (A) and during treatment (B). In (B), 
the body weight of animals was measured once a week until the end of treatment with NaCl 0.9% or SB 
(1mg/kg/day), during 42 days. When indicated (arrow), the animals were moved to behavioral test room for 
one week, presenting a tendency for a decrease in body weight. Statistical analysis: (A) Data are expressed as 
mean ± SEM of the number of animals depicted in the graph legend. Statistical analysis: ***p < 0.001 vs WT 
mice (Student’s t-test). 
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4.2 Influence of treatment with sodium butyrate in exploratory activity of 
3xTg-AD mice 
 
 At day 39 of treatment, the animals were subjected to a variation of the Y-maze 
test designed to evaluate recognition memory and exploratory activity. 3xTg-AD mice 
revealed a small tendency, although not significant, for a slight increase in the percentage of 
entries into the novel arm (41.00 ± 3.11 %, n= 10 for 3xTg-AD vs 35.04 ± 2.93 %, n= 10 for 
WT; p= 0.3831, One way ANOVA with Sidak post-test; Figure 18A), in the percent 
travelled distance in the novel arm (41.39 ± 3.57 %, n= 10 for 3xTg-AD vs 30.59 ± 2.66 %, 
n= 10 for WT; p= 0.0869, One way ANOVA with Sidak post-test; Figure 18B) and in the 
percentage of  time spent in the novel arm (39.43 ± 7.63 %, n= 10 for 3xTg-AD vs 34.01 ± 
4.88 %, n= 10 for WT; p= 0.8614, One way ANOVA with Sidak post-test; Figure 18C) 
compared to WT animals. Treatment of 3xTg-AD mice with SB had no effect on any of 
these behavioural parameters (39.17 ± 3.44 %, n= 12 for 3xTg-AD+SB vs 41.00 ± 3.11 %, 
n= 10 for untreated 3xTg-AD, p= 0.9020, for the entries into the novel arm; 38.81 ± 3.94 %, 
n= 12 for 3xTg-AD+SB vs 41.39 ± 3.57 %, n= 10 for untreated 3xTg-AD, p= 0.8426 for the 
distance travelled in the novel arm and 36.94 ± 8.85 %, n= 12 for 3xTg-AD+SB vs 39.43 ± 
7.63 %, n= 10 for untreated 3xTg-AD, p= 0.9661 for the time spent in the novel arm; One 
way ANOVA with Sidak post-test for Figure 18A-C). SB did not affect recognition memory 
and exploratory activity in 3xTg-AD mice. 
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Figure 18- Assessment of exploratory activity and locomotion by Y-maze test in 3xTg-AD mice treated 
with SB. At the 39th day of treatment, animals performed the Y-maze test. 120 min after the initial training 
session (that lasted for 8 min), the animals were allowed to explore all three arms (start, other and novel) for 8 
min. The percentage of entries (A), of travelled distance (B) and of time spent (C) in the novel arm were 
evaluated. The data are expressed as mean ± SEM of n=10 WT, n= 10 3xTg-AD and n= 12 3xTg-AD+SB. 
Statistical analysis was given by the one way-ANOVA test (for a parametric Gaussian distribution), followed 
by Sidak post-test. 
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4.3 Effect of sodium butyrate treatment on anxiety-like behaviour in 3xTg-AD 
mice 
 
 At the 40th day of treatment, the animals were subjected to the open field test to 
evaluate the anxiety-like behavior and locomotor activity. 3xTg-AD mice revealed a 
tendency for a decrease, although not significant in the time spent in the center of the box 
when compared to WT mice (23.44 ± 6.47 s, n= 11 for 3xTg-AD vs 52.85 ± 10.59 s , n= 10 
for WT; p= 0.1327, by the one-way ANOVA for multiple comparisons and a Gaussian 
distribution, with Sidak post-test; Figure 19A) and, therefore, a tendency (again not 
significant) for an increase in the time spent in the periphery of the arena (573.90 ± 8.50 s, 
n= 11 for 3xTg-AD vs 542.20 ± 10.59 s , n= 10 for WT; p= 0.4022, by the one-way ANOVA 
for multiple comparisons and a Gaussian distribution, with Sidak post-test; Figure 19B), 
showing a small tendency for increased anxiety like behavior in 3xTg-AD mice. Treatment 
of these mice with SB clearly increased the time spent in the center of the arena (45.57 ± 
12.61 s, n= 13 for 3xTg-AD+SB vs 23.44 ± 6.47 s, n= 11 for untreated 3xTg-AD; p=  
0.02608, by the one-way ANOVA for multiple comparisons and a Gaussian distribution, 
with Sidak post-test; Figure 19A), and  decreased, although not significantly, the time spent 
in the periphery of the arena (535.50 ± 19.34 s, n= 13 for 3xTg-AD+SB vs 573.90 ± 8.50 s, 
n= 11 for untreated 3xTg-AD; p= 0.1326, by the one-way ANOVA for multiple comparisons 
and a Gaussian distribution, with Sidak post-test; Figure 19B) when compared to untreated 
3xTg-AD mice. Furthermore, 3xTg-AD mice travelled a smaller distance than WT mice both 
in the center (1.041 ± 0.22 m, n= 11 for 3xTg-AD vs 2.03 ± 0.25 m, n= 10 for WT; p= 
0.0217, by the one-way ANOVA for multiple comparisons and a Gaussian distribution, with 
Sidak post-test; Figure 19C) and in the periphery of the arena (6.84 ± 0.61 m, n= 11 for 
3xTg-AD vs 10.60 ± 1.24 m, n= 10 for WT; p= 0.0109, by the one-way ANOVA for multiple 
comparisons and a Gaussian distribution, with Sidak post-test; Figure 19D). However, SB 
treatment had no significant effect on the distance travelled in center (1.19 ± 0.26 m, n= 13 
for 3xTg-AD+SB vs 1.04 ± 0.22 m, n= 11 for untreated 3xTg-AD; p= 0.8825, by the one-
way ANOVA for multiple comparisons and a Gaussian distribution, with Sidak post-test; 
Figure 19C) or in the periphery of the arena (6.59 ± 0.271 m, n= 13 for 3xTg-AD+SB vs 
6.84 ± 0.61 m , n= 11 for untreated 3xTg-AD; p= 0.9711, by the one-way ANOVA for 
multiple comparisons and a Gaussian distribution, with Sidak post-test; Figure 19D). After 
the treatment, we conclude that SB has no effect in anxiety-like behaviour in 3xTg-AD mice. 
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Figure 19- Evaluation of anxiety-like behaviour by the open field test in 3xTg-AD mice following 
treatment with SB. At the 40th day of treatment, animals performed the open-field test. They were allowed to 
move freely in the arena of box for 10 minutes. Time spent in center (A) and periphery (B), and distance 
travelled in center (C) and periphery (D) were evaluated. The data are expressed as mean ± SEM of n=10 WT, 
n= 11 3xTg-AD and n= 13 3xTg-AD+SB. Statistical analysis: *p< 0.05 vs. saline-treated WT mice, by the one 
way-ANOVA test (for a parametric Gaussian distribution), followed by Sidak post-test.  
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4.4 Effect of sodium butyrate treatment on spatial memory and recognition in 
3xTg-AD mice 
 At the 41st and 42nd days of treatment, the animals were subjected to the object 
displacement test to evaluate spatial memory and the novel object recognition to evaluate 
the recognition capacity, respectively. In the object displacement test, 3xTg-AD animals 
revealed a small tendency for a decrease in the recognition index (12.93 ± 8.86 %, n= 7 for 
3xTg-AD vs 53.59 ± 12.48 %, n= 9 for WT; p= 0.0813, by the Kruskal-Wallis test for 
multiple comparisons and a non- parametric distribution, with Dunn’s post-test, Figure 20A) 
compared to WT animals. Treatment of 3xTg-AD mice with SB revealed a very small 
tendency for an increase in the recognition index (37.33 ± 13.49 %, n= 11 for 3xTg-AD+SB 
vs 12.93 ± 8.86 %, n= 7 for untreated 3xTg-AD, p= 0.3427 Figure 20A), by the Kruskal-
Wallis test for multiple comparisons and a non-parametric distribution, with Dunn’s post-
test. In the novel object recognition test, we found no differences in performance between 
3xTg-AD and WT animals in the recognition index (17.65 ± 17.65 %, n= 5 for 3xTg-AD vs 
32.19 ± 16.31 %, n= 6 for WT; p> 0.9999, by the Kruskal-Wallis test for multiple 
comparisons and a non- parametric distribution, with Dunn’s post-test, Figure 20B). 
Furthermore, treatment of 3xTg-AD mice with SB had no effect in the recognition index 
compared to untreated 3xTg-AD mice (57.07 ± 23.39 %, n= 5 for 3xTg-AD+SB vs 17.65 ± 
17.65 %, n= 5 for untreated 3xTg-AD, p= 0.2865, by the Kruskal-Wallis test for multiple 
comparisons and a non-parametric distribution, with Dunn’s post-test, Figure 20B). In the 
both tests, the animals that met the exclusion criteria in the training phase according Vogel-
Ciernia and Wood, were excluded from the test phase (Vogel-Ciernia and Wood, 2014). 
Thus treatment with SB in 3xTg-AD mice had no effect on spatial memory and recognition 
capacity.  
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4.5 Influence of sodium butyrate on acetyl H3 levels in 3xTg-AD mice 
Considering that SB is a class I HDACi, we further examined the levels of histone 
acetylation. After the behavioral tests, the animals were euthanized, and total brain cortical 
extracts were obtained. The levels of acetylated and total histone H3 were evaluated by 
Western blotting and normalized against beta-actin for each sample. 3xTg-AD mice did not 
present a significant difference in acetyl H3 levels (0.51 ± 0.23, n= 8 for 3xTg-AD vs 1.00 
± 0.31, n= 8 for WT; p= 0.2776, by the Kruskal-Wallis test for multiple comparisons and a 
non-parametric distribution, with Dunn’s post-test Figure 21A) or in total H3 levels (1.01 ± 
0.27, n= 8 for 3xTg-AD vs 1.00 ± 0.48, n= 8 for WT; p= 0.9376, by the Kruskal-Wallis test 
for multiple comparisons and a non-parametric distribution, with Dunn’s post-test Figure 
21B) compared to WT animals. Treatment of 3xTg-AD mice with SB had no effect on acetyl 
H3 levels (0.82 ± 0.26, n= 11 for 3xTg-AD+SB vs 0.51 ± 1.10 , n= 8 for untreated 3xTg-
AD, p= 0.6303, by the Kruskal-Wallis test for multiple comparisons and a non-parametric 
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Figure 20- Evaluation of spatial memory (A) by object displacement test and recognition capacity (B) by 
novel object displacement test in 3xTg-AD mice treated with SB. At the 41st and 42nd days of treatment, 
animals performed the object displacement (A) and novel object recognition tests (B), to assess their spatial 
and recognition memory capacity. After a 10 min habituation to the open-field arena and the training sessions 
(10 min), during the test sessions for each behavioural procedure, the animals were allowed to move freely and 
explore two objects (in OD: one dislocated and one non-dislocated object; in NOR: novel and familiar objects) 
for 5 minutes. The recognition indexes were calculated as the ratio between the time spent exploring the 
dislocated/novel object and the total time spent exploring both objects. In OD test we excluded n=1 WT, n= 4 
3xTg-AD and n=3 3xTg-AD+SB and n= 4 WT, n= 6 3xTg-AD and n= 9 3xTg-AD+SB for NOR test. The data 
are expressed as mean ± SEM of n=9 WT, n= 7 3xTg-AD and n= 11 3xTg-AD+SB for OD test and n=6 WT, 
n= 5 3xTg-AD and n= 5 3xTg-AD+SB for NOR test Statistical analysis was given by the Kruskal-Wallis test 
(for a non-parametric distribution), followed by Dunn’s post-test. 
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distribution, with Dunn’s post-test Figure 21A) or total H3 levels (1.10 ± 0.24, n= 11 for 
3xTg-AD+SB vs 1.01 ± 0.27 , n= 8 for untreated 3xTg-AD, p> 0.9999, by the Kruskal-
Wallis test for multiple comparisons and a non-parametric distribution, with Dunn’s post-
test Figure 21B) compared to 3xTg-AD mice, either. Therefore, SB had no effect on acetyl 
H3 levels in 3xTg-AD mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21- Assessment of histone H3 acetylation in 3xTg-AD mice treated with sodium butyrate. Total brain 
cortical extracts were obtained by RIPA lysis buffer and probed by Western blotting for acetylated and total H3 
levels. Results are expressed as mean ± SEM of band intensities normalized to β-actin levels of n=8 WT, n= 8 
3xTg-AD and n= 11 3xTg-AD+SB. Statistical analysis was given by the Kruskal-Wallis test (for a non-parametric 
distribution), followed by Dunn’s post-test. 
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4.6 Impact of sodium butyrate treatment on pTau and Tau levels in 3xTg-AD 
mice 
 
The excessive phosphorylation of Tau at Thr231 inhibits the association of Tau to 
the microtubules (Sengupta et al., 1998) and p(Ser416)Tau, numbered according with the 
longest isoform of tau, was reported as being one of the main phosphorylation sites in vitro 
(Yamamoto et al., 2005). Considering that a protective therapeutic strategy could impact on 
AD-related biochemical phenotypes, we also determined Tau phosphorylation at Ser416 and 
Thr231 residues and total Tau levels by Western blotting in cortical samples of 3xTg-AD 
mice subjected to SB treatment. 3xTg-AD mice did not present a significant difference in 
the levels of phosphorylated Tau at Ser416 (1.27 ± 0.27, n= 8 for 3xTg-AD vs 1.00 ± 0.22, 
n= 8 for WT; p= 0.7714, Figure 22A), phosphorylated Tau at Thr231 (0.95 ± 0.24, n= 8 for 
3xTg-AD vs 1.00 ± 0.22, n= 8 for WT; p= 0.9866, Figure 22B) or total Tau levels (2.70 ± 
0.98, n= 8 for 3xTg-AD vs 1.00 ± 0.44, n= 8 for WT; p= 0.5406, Figure 22C), when 
compared to WT animals. Treatment of 3xTg-AD mice with SB had no effect in the levels 
of phosphorylated Tau at Ser416 (1.45 ± 0.29, n= 11 for 3xTg-AD + SB vs 1.27 ± 0.27, n= 
8 for 3xTg-AD; p= 0.8748, Figure 22A), phosphorylated Tau at Thr231 (0.94 ± 0.21, n= 11 
for 3xTg-AD + SB vs 0.95 ± 0.24, n= 8 for 3xTg-AD; p= 0.9996, Figure 22B) and total Tau 
levels (3.92 ± 1.43, n= 11 for 3xTg-AD + SB vs 2.70 ± 0.98, n= 8 for 3xTg-AD; p> 0.9999, 
Figure 22C) compared to untreated 3xTg-AD mice. One-way ANOVA with Sidak post-test 
for Figure 22A, B and Kruskal-Wallis test for multiple comparisons and a non-parametric 
distribution, with Dunn’s post-test for Figure 22C. At the end of the treatment, we concluded 
that SB had no effect on pTau and Tau levels in 3xTg-AD mice. 
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Figure 22- Assessment of Tau phosphorylation and Tau total levels in 3xTg-AD mice treated with SB. Total 
brain cortical extracts were obtained by RIPA lysis buffer and probed by Western blotting for p(Ser416)Tau, 
p(Thr231)Tau and total Tau primary antibodies. Results are expressed as mean ± SEM of band intensities 
normalized to β-actin levels of n=8 WT, n= 8 3xTg-AD and n= 11 3xTg-AD+SB. Statistical analysis was given 
by the one-way ANOVA test (for a parametric Gaussian distribution), followed by Sidak post-test (A), (B), and 
by the Kruskal-Wallis test (for a non-parametric distribution), followed by Dunn’s post-test (C). 
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4.7 Analysis of Nrf2 and phosphorylated Nrf2 in 3xTg-AD mice subjected to 
SB treatment 
 
Because AD pathology has been largely described to account for by increased 
formation of reactive oxygen species (Schipper et al., 1995) and Nrf2 was previously shown 
to be altered in the 3xTg-AD model (Mota et al., 2015), we also analyzed the total and 
phosphorylated levels of Nrf2 at Ser-40 in 3xTg-AD mice treated with SB. This residue is 
one of the four PKC-mediated phosphorylation sites in human and is critical for a signaling 
event in a cellular antioxidant response (e.g. Huang et al., 2002). 
Nrf2 total levels and p(Ser40)Nrf2 were evaluated by Western blotting after 
treatment with SB in 3xTg-AD mice and normalized against beta-actin signal for each 
sample. 3xTg-AD mice did not present a significant difference in Nrf2 levels (1.02 ± 0.07, 
n= 8 for 3xTg-AD vs 1.00 ± 0.13, n= 8 for WT; p= 0.9887, Figure 23A) neither pNrf2 levels 
(1.10 ± 0.23, n= 8 for 3xTg-AD vs 1.00 ± 0.24, n= 8 for WT; p= 0.9387, Figure 23B) 
compared to WT animals. Treatment of 3xTg-AD mice with SB had no effect in Nrf2 levels 
(0.82 ± 0.19, n= 11 for 3xTg-AD + SB vs 1.10 ± 0.23, n= 8 for 3xTg-AD; p> 0.5807, Figure 
23A) nor pNrf2 levels (0.89 ± 0.13, n= 11 for 3xTg-AD + SB vs 1.02 ± 0.07, n= 8 for 3xTg-
AD; p> 0.6679, Figure 23B) compared to 3xTg-AD mice. one-way ANOVA for multiple 
comparisons and a Gaussian distribution, with Sidak post-test for Figure 23A, B. SB had no 
effect on Nrf2 and pNrf2 levels in 3xTg-AD mice. 
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4.8 Characterization of neuropathology in 3xTg-AD and WT animals 
In order to clarify the histological hallmarks of AD phenotype of 3xTg-AD mice 
used in this work, Aβ deposition and phosphorylated Tau were examined in brain sections 
of 3xTg-AD versus WT by immunohistochemistry (IHC). Contrary to what was expected, 
we could not find evidence for intracellular Aβ accumulation (Figure 24D) nor extracellular 
Aβ plaques in the hippocampus of 10.5 months-old 3xTg-AD (Figure 24B) or age-matched 
WT mice (Figure 24A, C). Hyperphosphorylated Tau at Ser202 and Thr205 was not present 
in the hippocampus of 3xTg-AD when compared to age-matched WT mice (Figure 24E, F) 
either. 
 
 
 
 
 
 
 
Figure 23- Assessment of total and phosphorylated Nrf2 levels in 3xTg-AD mice treated with SB. Total 
brain cortical extracts were obtained by RIPA lysis buffer and probed by Western blotting for Nrf2 and 
p(Ser40)Nrf2 levels. Results are expressed as mean ± SEM of band intensities normalized to β-actin levels of 
n=8 WT, n= 8 3xTg-AD and n= 11 3xTg-AD+SB. Statistical analysis was given by the one-way ANOVA test 
(for a parametric Gaussian distribution), followed by Sidak post-test. 
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According to Oddo and colleagues, intracellular Aβ appears between 3 and 4 months 
of age (Oddo et al., 2003). Therefore, we evaluated by fluorescence immunohistochemistry 
if the 5-month 3xTg-AD animals (Figure 25A, B) as well as the animals used in this study 
(10.5 months) (Figure 25C, D) had this characteristic of the disease. As seen previously, no 
intracellular Aβ presence was observed in the analyzed slices of brain cortex. 
 
 
 
Figure 24- Analysis of Aβ and hyperphosphorylated Tau in 10.5 month-old 3xTg‐AD and WT mice. The 
histological hallmarks of AD phenotype of 3xTg-AD (B, D, F) and WT (A, C, E) mice used in this work were 
evaluate by IHC. The intracellular Aβ plaques (A, B), extracellular Aβ (C, D) and phosphorylated Tau (E, F) 
were evaluated in WT and 3xTg-AD mice. Images obtained in Zeiss Axio Imager Z2 microscope (Zeiss) using 
Plan-Apochromat 5x and 10x/0.8 M27 objectives. Scale bar: 50 µm.  
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Figure 25- Analysis of intracellular Aβ in 5 and 10.5 months-old 3xTg‐AD. The presence of intracellular 
Aβ plaques (red) were evaluated in slices of brain cortex of 5 months-old (A, B) and 10.5 months-old 3xTg-
AD mice (C, D). Nucleus was visualized by Hoechst staining (blue) and APP was immunostained with a 
specific antibody (green). Images obtained in Zeiss Axio Imager Z2 microscope (Zeiss) using Plan-
Apochromat 5x, 10x and 20x/0.8 M27 objectives. Scale bar: 10 µm for A and 50 µm for B, C and D.  
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AD is a progressive neurodegenerative disease with no effective treatment. 
Nevertheless, the study of epigenetic mechanisms is gaining importance to deepen the 
knowledge of disease factors and pathological mechanisms and, hopefully, to develop  
efficient treatments (Govindarajan et al., 2011). According to Li and colleagues (Li et al., 
2019), histone acetylation plays an important role in learning and memory, by allowing the 
relaxation of chromatin and subsequent gene transcription. Acetylation levels of histones 
were altered in AD, most likely due to the increased levels of HDAC in comparison with 
HATs, thereby decreasing gene transcription (Saha and Pahan, 2006). Indeed, both the 
sporadic and familial forms of AD were associated with increased DNA compaction and the 
consequent repression in DNA transcription. Several authors showed that, e.g., the APP/PS1 
(Francis et al., 2009) and the Tg2576 mouse models for AD (Ricobaraza et al., 2009) had 
lower levels of H4 acetylation. Accordingly, others showed that HDACi may constitute a 
therapeutic strategy against AD, since they allow for the increase in acetylation events. 
Particularly, HDACis can lower chromatin compaction, thereby increasing gene 
transcription (e.g., Schneider et al., 2013). These led us to evaluate the effects of peripheral 
SB (a HDACi) administration in the behavioural and cellular phenotypes of 9 months-old 
3xTg-AD mice.  
 
In the present study, 9 months-old 3xTg-AD animals had a significantly larger body 
weight compared to WT mice, before and during SB treatment. These results are in 
accordance with previous studies showing that 3xTg-AD mice were heavier than WT 
animals between the ages of 7 and 12 months (Knight et al., 2013, 2014). In addition, Knight 
and co-authors revealed that the 3xTg-AD animals have an increased appetite and food 
consumption (at least until 12 months of age) when compared to WT mice (Knight et al., 
2012). According to these authors, until the age of 6 months 3xTg-AD mice did not exhibit 
significant changes in their metabolic rates, because their larger body mass resulted from a 
higher food intake, whereas from the age of 7 months onwards, their energetic metabolism 
becomes altered, with the higher food intake in animals overexpressing Aβ becoming 
associated with weight loss. This led the authors to hypothesize that, with disease 
progression upon aging, the 3xTg-AD mice may undergo a hypometabolic state. Our results 
also showed a tendency for a decrease in body weight among all animal groups after their 
transfer to the behaviour room. This could be due to: i) an increased exploratory activity that, 
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together with an increased locomotion, could result in a higher energy expenditure; and/or 
ii) an increased anxiety-like behaviour and the subsequent reduction in food intake, thereby 
accounting for such slight weight loss. 
 
Our study showed no significant effects of treatment with SB on the behavioural tests 
on memory, learning capacity and anxiety in 3xTg-AD mice. Nevertheless, our observation 
of increased anxiety-like behaviour in saline-treated 3xTg-AD mice compared to saline-
treated WT mice partially agrees with studies showing that the 3xTg-AD mice presented 
high levels of anxiety between the ages of 7.5 and 11 months, together with difficulties in 
learning at 6 months of age (Giménez-Llort et al., 2007), weak memory (Stover et al., 2015) 
and locomotor impairment already in the pre-symptomatic phase (Buchman et al., 2011). In 
accordance with the behavioural changes described by Sterniczuk and colleagues 
(Sterniczuk et al., 2010a) in 7.5 to 11 month-old 3xTg-AD female mice, our male saline-
treated 3xTg-AD animals also presented higher latency time in the periphery in comparison 
with age-matched saline-treated WT mice, which spent more time in the center in the open-
field arena. This suggests that 3xTg-AD mice may be more anxious than WT ones. Similar 
observations were reported in 3xTg-AD animals, namely the less time spent in the center of 
the arena and the lower distance travelled (Filali et al., 2012; Pietropaolo et al., 2014; Pérez-
Corredor et al., 2019). Conversely, others reported that 12 month-old 3xTg-AD mice tended 
to be more hyperactive and slightly more anxious (though not statistically significant) than 
the WT mice (Pietropaolo et al., 2008, 2014). Hence, anxiety-like behaviour may arise at an 
initial stage of the disease, possibly before the onset of memory impairment. Even though 
the anxiety-like phenotype of 3xTg-AD mice was not significantly ameliorated by the 
peripheral treatment with SB, they tended to present less anxiety-like behaviour (as given by 
the slight increase in the time spent in the center of the arena and by the slight increment in 
the distance travelled) in comparison with saline-treated 3xTg-AD mice. Indeed, 
Govindarajan and co-authors (2011) showed that a 6-week administration of SB (1.2 
g/kg/day) to 15 month-old APP/PS1 AD mice at an advanced stage of the disease did not 
affect their anxiety levels, assessed by the open-field test. More specifically, they observed 
that the time and distance spent in the center and in the periphery of the arena were similar 
in APP/PS1 and WT mice. In a more recent study, Cao et al. (2018) observed that daily 
intraperitoneal injection of SB (1.2 g/kg/day) for 21 days did not affect the anxiety levels of 
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the forebrain presenilin-1 and presenilin-2 conditional double knockout (cDKO) mouse 
model for AD compared to WT mice. Of note, cDKO mice phenotype was similar to AD 
patients, and included memory deficits, Tau hyperphosphorylation and cerebral hypertrophy 
(Cao et al., 2018). 
 
Several studies involving the 3xTg-AD mice did not report significant differences in 
behavioural tests (like NOR and Morris Water Maze (MWM) tests) before the age of 9 
months, eventually with some impairment in short-term memory occurring at 6 month-old 
(Clinton et al., 2007; Martinez-Coria et al., 2010). Indeed, 6.5 months-old 3xTg-AD mice 
presented a weak recognition memory, and some locomotor and exploration deficits when 
compared to WT mice (Stover et al., 2015). At this respect, we did not observe significant 
differences in the number of entries nor in the time spent in the new arm of the Y-maze 
apparatus in saline-treated 3xTg-AD mice, though a slight increase in the travelled distance 
was observed in comparison with WT mice. This is in contrast with a previous report of less 
entries and time spent in the novel arm of the Y-maze apparatus by  11 month-old 3xTg-AD 
mice compared to WT mice (Carvalho et al., 2013). Surprisingly, Stover and colleagues 
found that 6.5 month-old 3xTg-AD mice even performed better than WT animals, which 
showed less spontaneous alternation (a measure of exploratory and spatial memory), as we 
also observed in the present study (Stover et al., 2015). This could be explained by the 
animals’ lower interest for novelty. Regarding the object displacement analysis, that aimed 
to evaluate the effect of SB in the spatial recognition capacity of an object, we observed a 
tendency towards a higher spatial memory performance in WT mice than in saline-treated 
3xTg-AD ones. This appears to be in line with a previous study in 3xTg-AD female mice 
(Davis et al., 2013). Treatment with SB tended to increase the recognition memory 
performance in 3xTg-AD mice compared with saline-treated 3xTg-AD mice, suggesting a 
slight improvement in their spatial memory. This is in accordance with the improvement in 
learning capacity and memory reported in 11 months-old CK-p25 AD mice after daily 
injections of SB (1.2 g/kg/day) for 4 weeks (Fisher et al., 2007). These mice exhibited 
progressive neuronal degeneration and death, increased Aβ levels and reduced synaptic 
plasticity, following p25 overexpression in forebrain neurons (Giusti-Rodríguez et al., 
2011). In addition, Cao and co-authors (2018) showed that intraperitoneal treatment with SB 
for 21 days increases the number of synapses, improving learning and long-term memory in 
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cDKO mice. In the last behavioural test performed in the present study, we used the novel 
object recognition test to evaluate the effect of SB treatment on the recognition capacity of 
3xTg-AD mice. Our observation that saline-treated 3xTg-AD mice did not present a 
significant deficit in the object recognition capacity compared to WT mice appears to 
contradict the previous evidence that the 3xTg-AD mice have deficits in the recognition 
capacity of objects (Filali et al., 2012). Adding to this, peripheral SB administration did not 
affect this behavioural trait in 3xTg-AD mice compared with saline-treated AD mice. This 
may be due to the fact that the animals did not learn the task properly during the training 
phase and/or did not reveal interest for the new object, as previously reported by Stover et 
al. (2015) and described above. Following Vogel-Ciernia and colleagues procedure, the mice 
that remained immobile in the box, or did not explore the two objects and/or presented 
repetitive movements during the training phase of NOR and OD tests were excluded from 
the testing phase (Vogel-Ciernia and Wood, 2014). In this behavioural test, the animals 
might have presented some tiredness, since the number of animals excluded in the last test 
(NOR) was higher when compared to the number of animals excluded in the OD test. 
 
SB was is a well-known inducer of histone acetylation (Fessler et al., 2013), whose 
main administration effect includes the increase in acetylation levels of histone H3 (Ferrante 
et al., 2003; Govindarajan et al., 2011), as described previously. Despite this, we did not find 
significant differences on brain cortical H3 acetylation levels between 3xTg-AD and WT 
mice, in contrast with its previously reported reduced levels (Fessler et al., 2013). Since SB 
is considered a HDACi that crosses the BBB (Liu et al., 2017), its lack of effect on histone 
acetylation under our experimental conditions was somehow unexpected. This could be due 
either to a suboptimal dose of SB used here in, to an inefficient drug distribution across the 
brain cortex and/or to its inefficient ejection from the pump (although the later maybe 
somehow unlikely, since most SB-treated 3xTg-AD mice displayed H3 acetylation levels in 
the range of those from saline-treated animals). However, we cannot exclude that SB 
diffusion across the BBB may have been inefficient, thereby reducing its therapeutic 
efficacy. This may explain the lack of SB effect on behavioural tests. 
Tau phosphorylation levels are often higher in brains from AD patients than in 
normal individuals (e.g., Li et al., 2019). Evidence point towards 40 potential sites for Tau 
protein phosphorylation in AD brains, including the Ser416 and Thr231 residues (Lin et al., 
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2013; Kimura et al., 2018). For instance, Green et al. (2008) showed an increased 
phosphorylation of Tau protein at Thr231 residue in the brains from 3xTg-AD mice, while 
more recently others reported that its excessive phosphorylation at this blunts its binding to 
the microtubules, damages cytoskeletal structure and function and, ultimately, the overall 
cellular structure (Li et al., 2019). However, in the present study we observed that brain 
cortical phosphorylation of Tau protein at Thr231 residue was similar in saline-treated 3xTg-
AD and WT mice. Adding to this, and in spite of constituting one of the main Tau protein 
phosphorylation sites in vitro (Yamamoto et al., 2005), no significant changes were found 
in brain cortical levels of Tau protein phosphorylation at the Ser416 residue (these are 
numbered according to the longest isoform of Tau protein) in 6 month-old 3xTg-AD versus 
WT mice (Gondard et al., 2019). Accordingly, we found that Tau protein phosphorylation 
at Ser416 was similar in 10.5 month-old, saline-treated 3xTg-AD and WT animals. Our 
results although demonstrate no effects of peripheral SB treatment on brain cortical Tau 
protein phosphorylation at Ser416 nor at Thr231 in 3xTg-AD animals. This was somehow 
unexpected, since Green et al. (2008) described that nicotinamide (an inhibitor of class III 
NAD+-dependent HDACs or sirtuins) administration in drinking water for 4 months to 4 
month-old 3xTg-AD mice diminished their levels of Tau protein phosphorylation at Thr231 
in comparison with untreated AD mice. However, the authors proposed that these changes 
were not directly related with transcription regulation, but rather with a nicotinamide-
mediated rescue in the Aβ oligomer-associated changes in Tau protein accumulation and 
degradation mechanisms (Tseng et al., 2008; Green et al., 2008). More specifically, 
nicotinamide may exert pleiotropic effects towards cytoskeleton, including the removal of 
Tau protein phosphorylation at Thr231 residue and subsequent tubulin acetylation that may 
ultimately reinforce microtubule stability (Green et al., 2008). Thus, this increased 
acetylation of tubulin (or eventually other post-translational modifications) may indirectly 
contribute for the lower Tau protein phosphorylation in AD, possibly by shifting the later 
towards microtubule stabilization and maintenance of cellular structure (Li et al., 2019). 
These data appear to agree with the decrease in hippocampal total phospho Tau protein levels 
found in AD Tg2576 mice intraperitoneally-administered with 4-PBA (200 mg/kg), another 
HDACi, between the ages of 7 and 12 months  (Ricobaraza et al., 2009). Surprisingly, we 
did not observe significant differences in total Tau protein levels in the brains from 3xTg-
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AD mice, neither after saline nor after SB administration, in contrast with other authors 
(Walls et al., 2014).  
Nrf2 is an active transcription factor under oxidative stress that was decreased in AD 
brains (Bahn and Jo, 2019). Recent studies showed that SB treatment stimulates the 
expression of Nrf2 and its target genes (namely HO-1 and NQO1) (Dong et al., 2017). 
Therefore, we aimed to evaluate the effect of SB treatment on brain Nrf2 levels in 3xTg-AD 
mice. We observed that brain cortical Nrf2 levels were similar between saline-treated WT 
and 3xTg-AD mice and that peripheral delivery of SB did not affect its total levels in 3xTg-
AD animals. This was somehow unexpected, since SB was recently shown to increase Nrf2 
expression in an animal model of diabetic nephropathy (Dong et al., 2017). In addition, no 
differences occurred in Nrf2 phosphorylation at Ser40 residue between saline-treated 3xTg-
AD and WT mice, in contrast with a previous study from our laboratory showing that 3 
month-old 3x-Tg-AD mice had higher brain cortical levels of phosphorylated Nrf2 at Ser40 
residue (Mota et al., 2015). In line with the above-mentioned maintenance of total Nrf2 
levels in 3xTg-AD mice, treatment with SB did not affect its phosphorylation at Ser40 
residue either. Since the Nrf2 pathway regulates the expression of antioxidant enzymes with 
different roles in the brain that depend the disease stage, cell type or its surrounding 
environment, we anticipate that the evaluation of Nrf2 in nucleic fractions, of its 
transcriptional activity and/or of the mRNA levels its target antioxidant and detoxifying 
proteins/enzymes would provide further insights herein. 
  
 The 3xTg-AD animal model was created in 2003 by LaFerla’s group and has been 
widely used to study AD pathophysiology. Unfortunately, recent data demonstrate that the 
latest generations of this transgenic line present initial and progression pathological features 
that clearly differ from the one initially described ones. Therefore, controversy exists 
nowadays regarding the use of the 3xTg-AD mice to model AD itself and, in particular, to 
the evaluate potential therapeutic strategies against its sporadic form (the vast majority of 
AD cases) (Belfiore et al., 2019). This is further supported by recent studies showing that 
Aβ plaques and hyperphosphorylated Tau protein deposition occur later than originally 
described by Oddo and collaborators (2003). Among them, Oddo and colleagues showed in 
2018 that 3xTg-AD female mice presented a spectrum of AD phenotypes at later ages than 
in the original characterization of the colony, including the appearance of an elevated 
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number of senile plaques only by the age of 12 months, and of neurofibrillary tangle 
accumulation (containing hyperphosphorylated Tau protein) between the ages of 12 and 20 
months. This delay in neuropathology occurs in spite of the higher susceptibility of females 
to AD (Carroll et al., 2010) and to depression (a condition widely associated with AD), 
alongside their pre-menopause and subsequent menopause phases starting at 12 to 14 
months-old, when their oestrogens and progestogens levels (and protective effects) suddenly 
drop (Ison and Allen, 2007). Overall, this points towards an even greater delay in the arousal 
of pathologic AD-like alterations in male 3xTg-AD mice, the only sex cohort used in the 
present study. To further characterize neuropathologically the WT and 3xTg-AD mice used 
in our experiments, we performed immunohistochemical analyses of AD-like hallmarks 
(including intra and extracellular Aβ and hyperphosphorylated Tau protein deposition) in 
brain tissue from 10.5 months-old animals. As in our previously described results, no 
significant differences were seen in AD-like neuropathological features in the 3xTg-AD 
compared to WT mice. This may thus justify the lack of significant behavioural and 
biochemical differences between the WT and AD mice consistently observed throughout the 
present work, despite the genotypic confirmation performed at the beginning of the study. 
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The 3xTg-AD mice were previously shown to present memory, learning and 
locomotion deficits, and anxiety-like behavior, being histopathologically characterized by 
the accumulation of Aβ aggregates and hyperphosphorylated Tau protein. Our main 
objective in the present study was to evaluate the effect of peripheral treatment with SB (an 
HDACi) as a possible therapeutic strategy against the disease phenotype.  
Our behavioral, biochemical and histological results showed that 10.5 months-old, 
saline-treated 3xTg-AD animals did not manifest most of the expected disease phenotypes. 
Despite their tendency for an increased anxiety, no memory deficit-related phenotypes were 
observed, suggesting that a shift of the AD phenotype towards older ages may have occurred. 
This may ultimately account for our unexpected results with the 3xTg-AD mice that, 
nonetheless, are in line with the very recent literature. It also reinforces the need for a re-
equate its use, especially when evaluating potential therapeutic strategies against sporadic 
AD. Besides performing similar experiments in another AD transgenic model (such as the 
APP/PS1 or 5xTg-AD mice), future studies should also include female mice and/or older 
animals, at a more severe AD stage. Since subcutaneous SB treatment did not increase 
histone acetylation (another contributor for the lack of differences in our experimental 
conditions), another possibility is the optimization of dosage, mode of administration and/or 
treatment duration with SB. 
In sum, our results support further studies addressing the role of peripheral HDACi 
against brain and behavioural changes that arise with AD progression along aging. This will 
ultimately advance our knowledge on AD pathophysiology and potential therapeutic 
strategies.  
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